VKTX
SHORT CANDIDATEMeanRevComposite
31.60
Technical
53.40
Fundamental
24.30
Rank
—
Price
33.43
Hurst
-0.04
As of
Jul 30, 2026
Dailyglp1 · LEADING
Viking Therapeutics, Inc.
HealthcareBiotechnologyViking Therapeutics is a clinical-stage pharmaceutical company developing treatments for disorders affecting metabolism and hormone regulation. The company's pipeline includes several drug candidates in various trial phases, such as VK2809 for liver disease, VK5211 for fracture recovery, VK0612 for metabolic conditions, VK2735 targeting weight management pathways, and VK0214 for a rare genetic neurological disorder. Based in San Diego, the company was founded in 2012.
Market cap
$3.5B
P/E (trailing)
—
P/E (forward)
-5.37
PEG ratio
—
Dividend yield
0.00%
Beta
0.65
52w range
23.82 – 43.15
Return on equity
-96.37%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 27.28 (-28.4%) · range 24.21–42.13
Cycle position
7/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 83 · STRONG SETUP · exit proximity 0
Conviction
45/ 100 · maturity 86%
VScore.3633
Buildup.2136
EMA entry setup.2783
Fundamentals.1624
Volume profile
POC
28.64
Price vs POC
-4.8%
Overhead supply
86%
Runway
+3.6%
Value area 24.98–36.93 · 86% of 120d volume overhead · heavy supply
Coverage
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trader-sentiment | 0.643 | Oct 29, 2026 |
| breakdown-signal | 0.516 | Oct 26, 2026 |
Pattern & cluster
Pattern
none
Cluster
LEADING · rank 7 · inflow
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -5.54% | -5.54% | 1/20d |
| 40d | -5.54% | -5.54% | 1/40d |